

Date of preparation: 2022-06-08

Abbreviated name of the Issuer: MABION S.A.

Subject matter: Extension of cooperation with Novavax

Legal basis: Article 17(1) of MAR – confidential information.

Content of the Report:

With reference to Current Report no. 52/2021 of 8 October 2021 on the conclusion of an agreement with Novavax, Inc. ("Novavax") relating to a commercial contract manufacturing agreement ("Manufacturing Agreement") and subsequent current reports on the expansion of cooperation with Novavax, the Management Board of Mabion S.A. ("Company") hereby informs that on 7 June 2022, in the night hours, the Company received a document signed by Novavax, providing for another extension of the scope of services under the Manufacturing Agreement in the form of Statement of Work #5 ("SOW#5").

The scope of SOW#5 covers stability testing of intermediate products and buffers produced and used in the manufacturing process of the SARS CoV-2 rS active substance, which is a component of the Nuvaxovid vaccine. The implementation of the work covered by SOW#5 will commence immediately after an arrangement is signed and will be completed in 2022. In the opinion of the Management Board, SOW#5 is of importance to the Company primarily due to the fact that it means a further stage of expansion of the cooperation with Novavax, and the tests covered by the present additional order will facilitate the management of the production process in the Company under the Manufacturing Agreement.